Your session is about to expire
← Back to Search
Clazakizumab for Kidney Transplant Rejection
Study Summary
This trial is testing a new drug to treat people with antibody mediated rejection, which is a serious form of allograft rejection. Clazakizumab, an anti-IL6 monoclonal antibody, will be given monthly for six to twelve doses, and patients will have biopsies at 6 and 12 months to check for improvement.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowTimeline
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Side effects data
From 2015 Phase 2 trial • 143 Patients • NCT02015520Trial Design
Find a Location
Who is running the clinical trial?
Media Library
- You haven't taken any experimental drugs in the past four weeks.I have an active CMV or EBV infection confirmed by blood tests.I have not had cancer in the past 5 years, except for certain skin cancers or cervical pre-cancer.I have had a multi-organ transplant.My kidney transplant is severely damaged.I haven't received any live vaccines in the last two months.I am between 15 and 75 years old.I have received the pneumococcal vaccine.My kidney function is severely reduced.I have not had an infection requiring antibiotics in the last 6 weeks.My biopsy shows chronic active antibody-mediated rejection and I have donor-specific antibodies.You have had an allergic reaction to monoclonal antibodies in the past.I am HIV-positive.I have or had inflammatory bowel disease, diverticular disease, or a gastrointestinal perforation.I do not have tuberculosis, confirmed by a negative Quantiferon test.
- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
- Group 1: Clazakizumab (Anti-IL-6 Monoclonal)
- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Frequently Asked Questions
Are we still able to enroll new patients in this clinical trial?
"Right now, this study is not enrolling patients. However, it was first posted on February 21st, 2018 and last edited on March 25th, 2022. Additionally, there are 71 other trials that are accepting participants at the moment."
Does this research opportunity extend to octogenarians?
"In order to be considered for this study, patients must fall between the ages of 15 and 75. There are 7 other clinical trials available for children under 18 and 71 additional options for seniors 65 and older."
Who might be best suited for this type of clinical research?
"The prerequisites for this particular clinical trial are as follows: the patient must have a kidney transplant, be between the ages of 15 and 75, and experience organ rejection. So far, around 10 people have met these qualifications and have been accepted into the study."
What other research exists on Clazakizumab's efficacy?
"There are currently 4 different clinical trials studying Clazakizumab. 1 of those is in Phase 3, while the others are still in earlier stages. The majority of these studies originate from Los Angeles, but there are 149 locations running investigations into this potential treatment."
Share this study with friends
Copy Link
Messenger